Opinion

Video

Understanding CML: Your Journey from Diagnosis to Treatment

Author(s):

Jorge E. Cortes, MD,Joannie Clements

A panel of experts on introduce a discussion on chronic myeloid leukemia (CML) with an overview of the disease, focusing on its subtypes and characteristics.

This program was made possible with support from Novartis Pharmaceuticals.

Video content above is prompted by the following questions:

  • Please provide some background on CML. What are the different subtypes of CML and how do they differ in terms of presentation and management?
  • Can you explain the typical prognosis and disease course for someone diagnosed with CML? How do you educate newly diagnosed patients on what to expect?
Related Videos
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
Dr. Tycel Phillips is an Associate Professor in the Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope in Duarte, California.
Dr. Richard “Rick" Winneker
Related Content
Itolizumab did not improve response rates at Day 29 in acute GVHD; however, the therapy showed significant benefits in long-term outcomes: © stock.adobe.com
March 27th 2025

Itolizumab Shows Long-Term Treatment Benefits in Acute GVHD

Ryan Scott
Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant benefits in long-term outcomes.
The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory leukemia or lymphoma: © nobeatsoffierce - stock.adobe.com
March 22nd 2025

First Patients Dosed in WU-CART-007 Trial for Blood Cancer Subtypes

Alex Biese
The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma.
FDA grants fast track designation to azer-cel in relapsed/refractory DLBCL: © stock.adobe.com
March 21st 2025

FDA Grants Fast Track Designation for Azer-Cel in Lymphoma Subset

Spencer Feldman
FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large B-cell lymphoma.
Darzalex and Revlimid maintenance improves survival following autologous stem cell transplantation in multiple myeloma: © stock.adobe.com.
March 18th 2025

Darzalex Plus Revlimid Improves Outcomes in Newly Diagnosed Myeloma

Alex Biese
Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell transplantation in multiple myeloma.
Orca-T improved survival free of moderate-to-severe cGVHD across leukemia subtypes: © nobeastsofierce - stock.adobe.com.
March 18th 2025

Orca-T Doubles Graft-Versus-Host Disease-Free Survival in Leukemia

Spencer Feldman
Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease across leukemia subtypes.
Felicia Mitchell is a survivor of stage 2b HER2-positive breast cancer diagnosed in 2010. Catch up on all of Felicia's blogs here!
March 17th 2025

A Picture is Worth Ten Thousand Words When it Comes to Cancer

Felicia Mitchell
Years after losing my brother to Hodgkin’s lymphoma, I learned something about how he felt facing a terminal diagnosis by studying an old Polaroid.